Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1009-1014

  Shimada, Toshiyuki ^a   Ueda, Masakazu ^a   Jinno, Hiromitsu ^a   Chiba, Naokazu ^a   Wada, Masahiro ^a   Watanabe, Junji ^b   Ishihara, Kazuhiko ^c   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epidermal growth factor receptor; MPC polymer; Paclitaxel; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOPARTICLE; PACLITAXEL; POLY[2 METHACRYLOYLOXYETHYLPHOSPHORYLCHOLINE CO BUTYL METHACRYLATE CO P NITROPHENYLOXYCARBONYL POLY(ETHYLENE GLYCOL)METHACRYLATE]; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; METHACRYLATES; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; PACLITAXEL; PHOSPHORYLCHOLINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 64949146011     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Crown J and O'Leary M: The taxanes: an update. Lancet 355: 1176-1178,2000.
2. Gelderblom H, Verweij J, Nooter K and Sparreboom A: Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37: 1590-1598, 2001.
3. Rowinsky EK and Donehower RC: Paclitaxel (taxol). N Engl J Med 332: 1004-1014, 1995.
4. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
5. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 705:211-225,2000.
6. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1: 1398-1402, 1987.
7. Hirota N, Ueda M, Ozawa S, Abe O and Shimizu N: Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti- epidermal growth factor receptor antibody. Cancer Res 49: 7106- 7109, 1989.
8. Osaku M, Ueda M, Ando N, Shinozawa Y, Hirota N, Shimizu N and Abe O: Targeted killing of squamous carcinoma cells by a monoclonal antibody-peplomycin conjugate which recognizes the EGF receptor. Anticancer Res 77: 1951-1956, 1991.
9. Ishihara K, Oshida H, Endo Y, Ueda T, Watanabe A and Nakabayashi N: Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 26: 1543-1552, 1992.
10. Ueda H, Watanabe J, Konno T, Takai M, Saito A and Ishihara K: Asymmetrically functional surface properties on biocompatible phospholipid polymer membrane for bioartificial kidney. J Biomed Mater Res 77: 19-27, 2006.
11. Moro T, Takatori Y, Ishihara K, Konno T, Takigawa Y, Matsushita T, Chung UI, Nakamura K and Kawaguchi H: Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis. Nat Mater 3: 829-836, 2004.
12. Ishihara K, Ueda T and Nakabayashi N: Preparation of phospholipid polymers and their properties as polymer hydrogel membranes. Polym J 22: 355-360, 1990.
13. Ishihara K, Iwasaki Y and Nakabayashi N: Polymeric lipid nanosphere consisting of water-soluble poly (2-methacryloy- loxyethyl phosphorylcholine-co- n-butyl methacrylate). Polym J 31: 1231-1236, 1999.
14. Konno T, Watanabe J and Ishihara K: Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloy-loxyethyl phosphorylcholine polymers. J Biomed Mater Res 65: 209-214, 2003.
15. Konno T, Watanabe J and Ishihara K: Conjugation of enzyme on polymer nanoparticles covered with phosphorylcholine groups. Biomacromolecules 5: 342-347, 2004.
16. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T and Wallace J: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guideline for the Welfare of Animals in Experimental Neoplasia (second edition). Br J Cancer 77: 1-10, 1998.
17. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD and Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268, 1990.
18. Rowinsky EK, Chaudhry V, Cornblath DR and Donehower RC: Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 75: 107-115, 1993.
19. Cabanes A, Briggs KE, Gokhale PC, Treat JA and Rahman A: Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol 72: 1035-1040, 1998.
20. Treat J, Damjanov N, Huang C, Zrada S and Rahman A: Liposomal- encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology (Williston Park) 15(Suppl 7): 44-48, 2001.
21. Schmitt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, Michaelis U, Naujoks K and Dellian M: Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 9: 2335-2341, 2003.
22. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK and Bang YJ: Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10: 3708-3716, 2004.
23. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN and Ellerhorst JA: Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8: 1038-1044, 2002.
24. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23: 7768-7771, 2005.
25. Moghimi SM, Hunter AC and Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev S3: 283-318,2001.
26. Mitra S, Gaur U, Ghosh PC and Maitra AN: Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 74: 317-323, 2001.
27. Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K and Kwon GS: Doxorubicin-loaded poly(ethylene glycol)-poly(beta- benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 64: 143-153, 2000.
28. Liggins RT and Burt HM: Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev 54: 192-202, 2002.
29. Chiba N, Ueda M, Shimada T, Jinno H, Watanabe J, Ishihara K and Kitajima M: Novel immunosuppressant agents targeting activated lymphocytes by biocompatible MPC polymer conjugated with interleukin-2. Eur Surg Res 39: 103-110, 2007.
30. Sakaki S, Tsuchida M, Iwasaki Y and Ishihara K: Water-soluble phospholipid polymer as a new biocompatible synthetic DNA carrier. Bull Chem Soc Jpn 77: 2283-2288, 2004.
31. Chiba N, Ueda M, Shimada T, Jinno H, Watanabe J, Ishihara K and Kitajima M: Development of gene vectors for pinpoint targeting to human hepatocytes by cationically modified polymer complexes. Eur Surg Res 39: 23-34, 2007.
32. Wada M, Ueda M, Ikeda T, Kitajima M, Konno T, Watanabe J and Ishihara K: Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel, Anticancer Res 27: 1431-1435, 2007.
33. Ozawa S, Ueda M, Ando N, Abe O and Shimizu N: High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int J Cancer 39: 333-337, 1987.
34. Peterson H: Organizing of the vascular structure in tumors. In: Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors, Peterson H (eds.). Boca Raton, FL, CRC press, pp. 31-39, 1979.
35. Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K, Doki Y, Hirano S and Takeichi M: Expression of immunoreactive E-cadherin adhesion molecules in human cancers. Am J Pathol 139: 17-23, 1991.
36. Brinkmann U and Pastan I: Immunotoxins against cancer, Biochem Biophys Acta 1198: 27-45, 1994.
37. Ozawa S, Ueda M, Ando N, Abe O, Hirai M and Shimizu N: Stimulation by EGF of the growth of EGF receptor-hyperproducing tumor cells in athymic mice. Int J Cancer 40:706-710, 1987.
38. Jinno H, Ueda M, Ozawa S, Ikeda T, Kitajima M, Maeda T and Seno M: The cytotoxicity of conjugate composed of human epidermal growth factor and eosinophil cationic protein. Anticancer Res 22: 4141-4146, 2002.
39. Hoshimoto S, Ueda M, Jinno H, Kitajima M, Futami J and Seno M: Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells. Anticancer Res 26: 857-864, 2006.